AMGN
Price
$412.96
Change
+$10.36 (+2.57%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
226.05B
27 days until earnings call
Intraday BUY SELL Signals
NVS
Price
$143.25
Change
+$2.47 (+1.75%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
278.08B
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMGN vs NVS

AMGN vs NVS Comparison Chart in %
View a ticker or compare two or three
VS
AMGN vs. NVS commentary
Oct 07, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and NVS is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
AMGN vs NVS: Fundamental Ratings
AMGN
NVS
OUTLOOK RATING
1..100
778
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
912
SMR RATING
1..100
1533
PRICE GROWTH RATING
1..100
4460
P/E GROWTH RATING
1..100
2721
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as AMGN (8) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (9) in the Biotechnology industry is in the same range as NVS (12) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

AMGN's SMR Rating (15) in the Biotechnology industry is in the same range as NVS (33) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

AMGN's Price Growth Rating (44) in the Biotechnology industry is in the same range as NVS (60) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

NVS's P/E Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as AMGN (27) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNNVS
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
54%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
50%
Momentum
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
51%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 9 days ago
61%
Bullish Trend 10 days ago
54%
Declines
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bearish Trend 2 days ago
48%
N/A
COMPARISON
Comparison
Oct 07, 2026
Stock price -- (AMGN: $402.60 vs. NVS: $140.79)
Brand notoriety: AMGN: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 67% vs. NVS: 78%
Market capitalization -- AMGN: $226.05B vs. NVS: $278.08B
AMGN [@Pharmaceuticals: Major] is valued at $226.05B. NVS’s [@Pharmaceuticals: Major] market capitalization is $278.08B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.06T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $200.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 4 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).

  • AMGN’s FA Score: 4 green, 1 red.
  • NVS’s FA Score: 4 green, 1 red.
According to our system of comparison, AMGN is a better buy in the long-term than NVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • AMGN’s TA Score: 6 bullish, 4 bearish.
  • NVS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AMGN is a better buy in the short-term than NVS.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -4.97% price change this week, while NVS (@Pharmaceuticals: Major) price change was -3.38% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.47%. For the same industry, the average monthly price growth was -6.11%, and the average quarterly price growth was +7.03%.

Reported Earning Dates

AMGN is expected to report earnings on Nov 03, 2026.

NVS is expected to report earnings on Oct 27, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-2.47% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
AMGN
Daily Signal:
Gain/Loss:
NVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLF2.580.09
+3.61%
Tandy Leather Factory
D62.000.98
+1.61%
Dominion Energy
MIDD105.920.81
+0.77%
Middleby Corp
STAA22.15-0.42
-1.86%
STAAR Surgical Company
RAIL6.60-0.16
-2.37%
FreightCar America